A whole genome screen for linkage disequilibrium in multiple sclerosis performed in a continental Italian population
Maria Liguori(University of Bari Aldo Moro), Patricia Momigliano‐Richiardi(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Stefania Cannoni(Sapienza University of Rome), Sandra D’Alfonso(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Luca Massacesi(National Institute of Neurological Disorders and Stroke), Efrosini Setakis(MRC Biostatistics Unit), María Trojano(University of Bari Aldo Moro), Giovanni Savettieri(University of Palermo), Roberto Bomprezzi(Sapienza University of Rome), Marta Mellai(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Gıancarlo Comı(Casa di Cura Columbus), Mara Giordano(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Paolo Aridon(University of Palermo), Maurizio Leone(Mario Negri Institute for Pharmacological Research), Tiziana Biagioli(University of Florence), Marco Salvetti(Istituto Neurologico Mediterraneo), Paola Naldi(Ospedale Maggiore), Clara Ballerini(University of Florence), Giulia Malferrari(University of Iowa), Pasquale Ferrante(University of Milan), Ida Biunno(University of Pavia), Stephen Sawcer(University of Cambridge), Giuseppe Salemi, Paolo Livrea(University of Bari Aldo Moro), Giovanni Ristori, Franca Rosa Guerini(Don Carlo Gnocchi Foundation), Isabella Ferro(Ospedale Maggiore), Cinzia Gellera(Fondazione IRCCS Istituto Neurologico Carlo Besta), Anna Repice, Luigi M.E. Grimaldi, C. Milanese(Fondazione IRCCS Istituto Neurologico Carlo Besta), Francesca De Robertis(University of Bari Aldo Moro), La Mantia Loredana(Fondazione IRCCS Istituto Neurologico Carlo Besta), Alastair Compston, Domenico Caputo(Don Carlo Gnocchi Foundation)
Cited by 19
Related Papers
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis
|Nature|2011|2.8k
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
|New England Journal of Medicine|2010|2.2k
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
|New England Journal of Medicine|2016|2k
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis
|Nature Genetics|2013|1.5k